Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCT917)

• Drug Name: CLL1-specific gene-engineered T cells Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMCT917

Molecule-Related Drug Atlas

Drug(s) Targeting Myeloid inhibitory C-type lectin-like receptor (CD371)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CD123/CLL1 CAR-T Cells	DM45Z3P	Acute myeloid leukaemia	2A60	Phase 2/3	[2]
CLL1 CAR-T Cell	DMUOMBZ	Acute myeloid leukaemia	2A60	Phase 2/3	[2]
CAR-T cells targeting CLL1	DMCPM92	leukaemia	2A60-2B33	Phase 1/2	[3]
Tepoditamab	DMC84Y9	Acute myelogenous leukaemia	2A41	Phase 1	[4]
CLL1-CD33 cCART cell therapy	DM5EM04	Acute myeloid leukaemia	2A60	Phase 1	[5]
CLT030	DM674MP	Acute myeloid leukaemia	2A60	Phase 1	[6]
KITE-222	DMPF49Z	Acute myeloid leukaemia	2A60	Phase 1	[7]
UCART-CLL1	DMT06MI	Multiple myeloma	2A83	Preclinical	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Myeloid inhibitory C-type lectin-like receptor (CD371)	TT70N8V	CL12A_HUMAN	CAR-T-Cell-Therapy	[1]

References

• [1] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [2] ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
• [3] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [4] MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733.
• [5] Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
• [6] Clinical pipeline report, company report or official report of Cellerant Therapeutics.
• [7] Clinical pipeline report, company report or official report of Gilead
• [8] Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.